Schnitzler Syndrome Medication

Updated: Mar 12, 2019
  • Author: Brian J Thomas, MD; Chief Editor: Dirk M Elston, MD  more...
  • Print
Medication

Medication Summary

The goals of pharmacotherapy are to reduce morbidity and to improve quality of life.

Next:

Interleukin-1 Receptor Antagonist

Class Summary

Agents in this category antagonize immune responses activated by interleukin (IL)‒1 receptor binding.

Anakinra (Kineret)

Anakinra is a recombinant, nonglycosylated form of the human IL-1 receptor antagonist (IL-1Ra). It competitively and selectively inhibits IL-1 binding to the type I receptor.

Previous
Next:

Anti-Interleukin 1-beta Antibody

Class Summary

Agents in this class have been shown to be effective in improving symptoms and decreasing markers of inflammation.

Canakinumab (Ilaris)

Canakinumab reduces inflammation by preventing interaction of IL-1 beta with cell surface receptors.

Previous
Next:

Uricosuric Agents

Class Summary

Agents in this class can reduce acute inflammation and pain.

Colchicine (Colcrys, Mitigare)

Colchicine inhibits microtubules and, as a result, may inhibit neutrophil chemotaxis and phagocytosis. It also may inhibit prostaglandin generation.

Previous
Next:

Antimalarial Agents

Class Summary

Antimalarials may work through numerous proposed mechanisms, mediating subtle immunomodulation without causing overt immunosuppression.

Hydroxychloroquine sulfate (Plaquenil)

This agent inhibits chemotaxis of eosinophils and locomotion of neutrophils and impairs complement-dependent antigen-antibody reactions, which, in turn, may prevent inflammatory reactions.

Previous
Next:

Antineoplastics, Tyrosine Kinase Inhibitor

Ibrutinib (Imbruvica)

Ibrutinib inhibits the function of Bruton tyrosine kinase (BTK). BTK is a key signaling molecule of the B-cell receptor-signaling complex that plays an important role in the survival of malignant or pathogenic B cells.

Previous